Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iridex (IRIX) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Iridex (IRIX) over the last 17 years, with Q3 2025 value amounting to $5.6 million.

  • Iridex's Cash & Equivalents rose 4437.82% to $5.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.6 million, marking a year-over-year increase of 4437.82%. This contributed to the annual value of $2.4 million for FY2024, which is 6606.48% down from last year.
  • Iridex's Cash & Equivalents amounted to $5.6 million in Q3 2025, which was up 4437.82% from $6.8 million recorded in Q2 2025.
  • In the past 5 years, Iridex's Cash & Equivalents registered a high of $28.0 million during Q2 2021, and its lowest value of $2.4 million during Q4 2024.
  • For the 5-year period, Iridex's Cash & Equivalents averaged around $12.7 million, with its median value being $10.4 million (2023).
  • Its Cash & Equivalents has fluctuated over the past 5 years, first soared by 15130.62% in 2021, then plummeted by 6606.48% in 2024.
  • Over the past 5 years, Iridex's Cash & Equivalents (Quarter) stood at $25.6 million in 2021, then crashed by 45.55% to $13.9 million in 2022, then tumbled by 49.48% to $7.0 million in 2023, then crashed by 66.06% to $2.4 million in 2024, then soared by 133.47% to $5.6 million in 2025.
  • Its Cash & Equivalents was $5.6 million in Q3 2025, compared to $6.8 million in Q2 2025 and $7.2 million in Q1 2025.